Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

REINACH, Switzerland, April 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it will host a conference call on Thursday 17 April 2008 at 8.30am CET. In this conference call, a leading expert will discuss the medical need and developments in the area of anti-infective drugs as well as the outcome of a recent meeting of the Anti-Infective Drugs Advisory Committee. During that meeting, the committee discussed product development and clinical trial design for both mild/moderate and moderate/severe community acquired pneumonia (CAP). A primary objective for the committee deliberations was to discuss issues relating to clinical trial design.

During the conference call, Arpida will also discuss the clinical data from the ASSIST-1 and ASSIST-2 trials with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI). In addition, the pooled analysis of the clinical data from these two pivotal Phase III trials will be discussed. Part of the data has already been published in earlier press releases, some additional statistical data, not previously published, will also be discussed. All data, as well as the dial-in details, will be made available via a press release on 17 April, prior to the conference call.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been co
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... IDEXX Laboratories, Inc. (NASDAQ: IDXX ) ... over 100,000 specimens to IDEXX Reference Laboratories for symmetric ... days since the breakthrough kidney function test launched in ... cause of suffering and death in cats and dogs. ... generally accepted kidney disease prevalence data showing that 1 ...
(Date:7/25/2015)... , ... July 25, 2015 , ... ... its refractometer series. It precisely checks and adjusts the surface temperature of the ... , In the pharmaceutical industry, data traceability and documentation are key requirements. It ...
(Date:7/24/2015)... Equity Research Institute has initiated ... PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ... Inc. (NASDAQ: NWBO ), and Acorda Therapeutics Inc. ... BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI On ... 5,146.41, down 0.49%, the Dow Jones Industrial Average declined ...
(Date:7/24/2015)... -- Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the ... China , today announced that the Company will report ... 30, 2015, before the market opens on Wednesday, August 5th, ... August 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... To participate in the call, please dial the following numbers ...
Breaking Biology Technology:Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3
... October 18 Astex Therapeutics Ltd.,today announced that ... and,AT13148, will be presented at the 2007 AACR-NCI-EORTC ... be held October,22-26, 2007 in San Francisco. ... Kinase (CDK),inhibitor currently in multi-centre Phase 1 clinical ...
... First Combination of Large Molecules to Show Drug-like Properties and ... ... Abbott (NYSE: ABT ),reported today that its scientists ... function and specificity of two or more,monoclonal antibodies (mAbs) into ...
... --, SAN DIEGO, CA, Oct. 18 /PRNewswire-FirstCall/ ... Company,has completed enrollment of the first cohort in ... and tolerability of new HspE7 in patients with,cervical ... to dose up to 5 cohorts comprising twenty-four,patients. ...
Cached Biology Technology:Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 3Abbott Scientists Create One Molecule With Two Antibody Functions 2Abbott Scientists Create One Molecule With Two Antibody Functions 3Nventa updates progress of cervical dysplasia trial with new HspE7 2Nventa updates progress of cervical dysplasia trial with new HspE7 3Nventa updates progress of cervical dysplasia trial with new HspE7 4Nventa updates progress of cervical dysplasia trial with new HspE7 5
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... the embryo. It is here that uniform cells divide ... like skeletal and digestive systems. Although biologists have known ... cell to express certain genes so as to become ... has not been a clear framework explanation of how ...
... State University School of Medicine physician researcher has received ... study the role of vitamin D in halting and ... blood pressure. Phillip Levy, M.D., M.P.H., associate professor ... will use the five-year grant to determine how vitamin ...
... study technique, University of Illinois researchers have seen ... an important family of neurotransmitter-gated ion channels. ... published their work in the journal Nature ... the membranes of nerve and muscle cells that ...
Cached Biology News:From pre-gut cells to glory 2From pre-gut cells to glory 3From pre-gut cells to glory 4Wayne State to study the role of vitamin D in African-Americans with high blood pressure 2Wayne State to study the role of vitamin D in African-Americans with high blood pressure 3Small change makes a big difference for ion channels 2Small change makes a big difference for ion channels 3
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
... stimulating factors for assays of mouse hematopoietic ... fetal liver. Suitable for the growth ... when added to methylcellulose at a final ... Will also support growth of mouse ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
...
Biology Products: